Karo Pharma acquires Reckitt's dermatology brand E4
Around one month after announcing the EUR 290m acquisition of Sylphar, Swedish Karo Pharma has once again taken out the big chequebook to acquire access to dermatology brand E45.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Since 2019, Swedish Karo Pharma has completed acquisitions for over USD 1.5bn (DKK 10bn), and yet it seems the thirst for new assets hasn't been quenched.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma starts phase II trial of Korean tablet
For subscribers
Stockholm wants to become leading life science region
For subscribers
.jpg&w=384&q=75)
